Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

Inclusion Criteria

• •PRIOR TO STEP 1 REGISTRATION
• •Score of \< 9 on the PHQ-4
• •Patients must have a FSFI desire subscale baseline score less than 3.3
• •* NOTE-Both the PHQ-4 and FSFI must be completed by the patient and data entered in Oncology Patient Enrollment Network (OPEN) at Step 1 registration to determine eligibility
• •Diagnosis of breast or gynecologic cancer \[examples are lobular carcinoma in situ (LCIS),ductal carcinoma in situ (DCIS), invasive breast, ovarian, endometrial, vulvar, cervical and vaginal\]
• •Completed definitive therapy consisting of surgery, chemotherapy or radiation therapy at least 180 days ago (may continue on Herceptin or endocrine therapy)
• •Post menopausal as defined by at least ONE of the following:
• •* 12 months (365 days) without a period;
• •* Bilateral oophorectomy;
• •* Chemically induced menopause as long as there are no plans to stop during the study;
• •* For women 57 and under, if at least one ovary and woman has had hysterectomy, must have follicle stimulating hormone (FSH) (\> 30 mIU/mL) and estradiol in menopausal range per institution?s laboratory (\< 10 for ultra sensitive assay: \< 25-30 otherwise);
• •* At least one ovary intact and 180 days without a period with FSH (\> 30 mIU/mL) and estradiol in menopausal range per institution's laboratory (\< 10 for ultra sensitive assay: \< 25-30 otherwise); Note: Women 58 and older do not have to have hormonal tests.
• •History, physical and performance status of 2 or less within 180 days prior to registration
• •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 x upper limit of normal (ULN)
• •Total bilirubin =\< 1.5 x ULN
• •Glomerular filtration rate \> 90ml/min
• •For breast cancer patients only, endocrine therapies are allowed (such as aromatase inhibitors, but not current tamoxifen. Prior tamoxifen is permitted with a 30 day wash out period). )
• •Vaginal estrogen is allowed, for all protocol disease sites, if dose equal to or less than that in estring (\< 7.5 mcg) and it has been used for at least 30 days with no plans to stop or alter use during the course of the study
• •Antidepressants for mood and hot flashes, including selective serotonin reuptake inhibitors (SSRIs) will be allowed if patients have been on a stable dose for the last 60 days and the dose is not expected to change during the course of the study; only subthreshold or low dose antidepressants will be allowed (e.g. Effexor up to 75 mg or Lexapro 5-10 mg or Celexa 10- 20 mg)
• •The patient must provide study-specific informed consent prior to study entry/screening
• •Women who report that their motivation/desire for sexual intimacy has decreased since her cancer diagnosis
• •Able to swallow whole capsules
• •Proficient in English (due to number of questionnaires not validated in other languages)
• •Completion of the FSFI and PHQ-4; both questionnaires will be required and data entered at the time of step 1 registration
• •PRIOR TO STEP 2 RANDOMIZATION
• •Completion of the following baseline quality of life forms: PHQ-4, FSFI, PROMIS sexual function and satisfaction, PROMIS fatigue short form 8a, Impact of Treatment Scale, patient reported outcomes (PRO)-Common Terminology Criteria for Adverse Events (CTCAE) items, and revised dyadic adjustment scale; these quality of life forms will be required and data must be entered in Medidata Rave at step 2 registration; if available at the time of step 1 registration, step 2 registration can take place immediately after step 1; women who do not currently have a partner do not have to complete the revised dyadic adjustment scale; enter "no partner" for this form